Table 4.
Comparison of risk groups
| Model | Risk group | Ototox. (number, %) | Controls (number, %) | OR (95% CI)a | P-valuea | Sens | Spec | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|
| TPMT only | Risk haplotype carriersb | 43 (91.5%) | 4 (8.5%) | 9.3 (3.1, 27.4) | 5.5 × 10−5 | 22.3% | 96.8% | 91.5% | 44.4% |
| Non-carriers | 150 (55.6%) | 120 (44.4%) | |||||||
| TPMT, ABCC3, COMT | High (>0.8) | 39 (92.9%) | 3 (7.1%) | 11.0 (3.2, 37.6) | 1.3 × 10−4 | 20.2% | 97.6% | 92.9% | 44.0% |
| Low plus intermediate (<0.8) | 154 (56.0%) | 121 (44.0%) | |||||||
| TPMT, ABCC3, COMT | High plus intermediate(>0.4) | 185 (64.5%) | 102 (35.5%) | 4.8 (1.9, 11.9) | 7.1 × 10−4 | 95.9% | 17.7% | 64.5% | 73.3% |
| Low (<0.4) | 8 (26.7%) | 22 (73.3%) | |||||||
| Clinical + TPMT, ABCC3, COMT | High (>0.80) | 97 (91.5%) | 9 (8.5%) | 8.8 (4.0, 19.2) | 5.5 × 10−8 | 50.3% | 92.7% | 91.5% | 54.5% |
| Low plus intermediate (<0.8) | 96 (45.5%) | 115 (54.5%) | |||||||
| Clinical + TPMT, ABCC3, COMT | High plus intermediate(>0.45) | 161 (73.2%) | 59 (26.8%) | 3.1 (1.6, 5.9) | 4.3 × 10−4 | 83.4% | 52.4% | 73.2% | 67.0% |
| Low (<0.45) | 32 (33.0%) | 65 (67.0%) |
CI, confidence interval; NPV, negative predictive value; OR, odds ratio; Ototox, ototoxicity; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.
a
Adjusted for age, vincristine treatment, germ-cell tumor, and cranial irradiation.
b
Risk haplotype carriers are individuals that are heterozygous or homozygous for TPMT rs12201199 risk variant.